• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, May 14 GlaxoSmithKline (GSK) Pharma has signed a co-promotion agreement with Daiichi Sankyo India Pharma Ltd for anti-hypertensive drug Olmesartan Medoxomil and its combination products. The agreement also marks Daiichi Sankyo India Pharma’s entry into India.

Daiichi Sankyo India is a subsidiary of Japanese pharma company Daiichi Sankyo Company Ltd. Olmesartan is an original research product of Daiichii Sankyo, grossing revenues of $ 2 billion for the company, a GSK Pharma note said. Dr Hasit Joshipura, Managing Director of GSK India, said that the agreement followed its other in-licensing agreement on Micafungin last week. “Our strategy, as laid out at the beginning of the year, of in- licensing products in specific high growth therapeutic areas is being rolled out and is well on track,” he said in the statement.

The note also quoted Mr V. Vijayendran, President of Daiichi Sankyo India saying that the arrangement met specific requirements of both organisations in terms of participation in the cardiology segment.

More Stories on : Alliances & Joint Ventures | Glaxosmithkline Pharmaceuticals Ltd | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Castrol India sets up 100th BikeZone

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line